Plain-English translation of NCT06245330 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing a new cancer medication called in patients with advanced solid tumors that have spread or cannot be surgically removed. Researchers want to find the right dose, understand how the body processes the medication, and see whether it helps shrink tumors. The trial has two phases: first, doctors will gradually increase the dose to find what works best and is safe, then they will test that dose specifically in patients with pancreatic cancer.
Many people with advanced solid tumors have limited treatment options once standard therapies stop working. This medication may offer a new approach by targeting a specific enzyme involved in cancer growth, potentially providing hope for patients who need additional treatment options.
You likely qualify if…
You likely don't qualify if…
If you are in the first phase, you will receive the medication as an intravenous infusion on Days 1, 8, and 15 of each 28-day cycle, starting at a low dose that will be gradually increased as researchers determine safety. If you are selected for the pancreatic cancer phase, you will receive the medication at the safe and effective dose identified in Phase 1, also given as infusions three times per cycle. You will have regular clinic visits, blood tests, and imaging scans to monitor how you are responding and watch for side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Ascentawits Pharmaceuticals, Ltd
Enrollment target
~180 participants
Started
July 2022
Primary completion
August 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Claire Hao
Study Principal Investigator
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.